Jaguar Health Inc (JAGX)
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal disorders in people and animals. The company operates through two business segments, Animal Health and Human Health, and develops both prescription and non-prescription products for companion and production animals as well as human patients. Its commercial portfolio includes Mytesi, an anti-secretory antidiarrheal medicine for adults with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, a prescription treatment for chemotherapy-induced diarrhea in dogs. Jaguar Health is also advancing Crofelemer for several diarrhea-related indications, including studies in adult cancer patients and selected rare diseases, along with Mytesi in additional clinical programs and NP-300, a second-generation antidiarrheal candidate. The company is headquartered in San Francisco, California, and its common stock trades on NASDAQ under the ticker JAGX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-JAGX
|
$1.67
|
25.9% Upside
|
Undervalued
|
$262.50 19,711.3% Upside
|
—
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
0.0x
|
-0.1x
|
0.0x
|
762.964 K
|
35.736 M
|
79.8%
|
95.6%
|
-28.1
|
—
|
15.1%
|
